From the Journals

Small Bowel Dysmotility Brings Challenges to Patients With Systemic Sclerosis


 

TOPLINE:

Patients with systemic sclerosis (SSc) who exhibit abnormal small bowel transit are more likely to be men, experience more severe cardiac involvement, have a higher mortality risk, and show fewer sicca symptoms.

METHODOLOGY:

  • Researchers enrolled 130 patients with SSc having gastrointestinal (GI) symptoms (mean age at symptom onset, 56.8 years; 90% women; 81% White) seen at the Johns Hopkins Scleroderma Center, Baltimore, from October 2014 to May 2022.
  • Clinical data and serum samples were longitudinally collected from all actively followed patients at the time of enrollment and every 6 months thereafter (median disease duration, 8.4 years).
  • Participants underwent whole gut transit scintigraphy for the assessment of small bowel motility.
  • A cross-sectional analysis compared the clinical features of patients with (n = 22; mean age at symptom onset, 61.4 years) and without (n = 108; mean age at symptom onset, 55.8 years) abnormal small bowel transit.

TAKEAWAY:

  • Men with SSc (odds ratio [OR], 3.70; P = .038) and those with severe cardiac involvement (OR, 3.98; P = .035) were more likely to have abnormal small bowel transit.
  • Sicca symptoms were negatively associated with abnormal small bowel transit in patients with SSc (adjusted OR, 0.28; P = .043).
  • Patients with abnormal small bowel transit reported significantly worse (P = .028) and social functioning (P = .015) than those having a normal transit.
  • A multivariate analysis showed that patients with abnormal small bowel transit had higher mortality than those with a normal transit (adjusted hazard ratio, 5.03; P = .005).

IN PRACTICE:

“Our findings improve our understanding of risk factors associated with abnormal small bowel transit in SSc patients and shed light on the lived experience of patients with this GI [gastrointestinal] complication,” the authors wrote. “Overall, these findings are important for patient risk stratification and monitoring and will help to identify a more homogeneous group of patients for future clinical and translational studies,” they added.

SOURCE:

The study was led by Jenice X. Cheah, MD, University of California, Los Angeles. It was published online on October 7, 2024, in Rheumatology.

LIMITATIONS:

The study may be subject to referral bias as it was conducted at a tertiary referral center, potentially including patients with a more severe disease status. Furthermore, this study was retrospective in nature, and whole gut transit studies were not conducted in all the patients seen at the referral center. Additionally, the cross-sectional design limited the ability to establish causality between the clinical features and abnormal small bowel transit.

DISCLOSURES:

The study was supported by grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The authors declared no conflicts of interest.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article appeared on Medscape.com.

Recommended Reading

Hypnosis May Offer Relief During Sharp Debridement of Skin Ulcers
MDedge Rheumatology
Trial Looks at Early Use of Mycophenolate to Reduce Flares, Nephritis
MDedge Rheumatology
Patient Navigators in Rheumatology Set to Expand in Importance, Scope With New Medicare Codes
MDedge Rheumatology
Direct-to-Consumer Testing’s Expansion to Rheumatology Has Benefits but Potential Risks
MDedge Rheumatology
Could Eyelid Imaging Aid Early Diagnosis of Sjögren Disease?
MDedge Rheumatology
Severe Autoimmune Diseases Linked to Premature Ovarian Insufficiency
MDedge Rheumatology
Dermatomyositis Cancer Screening Guidelines Get Real-World Validation
MDedge Rheumatology
Frailty, Not Just Advanced Age, Affects ANCA Vasculitis Outcomes
MDedge Rheumatology
Avoid Too Low or High Vitamin D Levels for Best Pregnancy Outcomes in Lupus
MDedge Rheumatology
Group Aims to Better Define ‘Extraordinarily Heterogeneous’ Mast Cell Activation Syndrome
MDedge Rheumatology